What is NNNN's Value Score?

Anbio Biotechnology - Class A Ordinary Shares (NNNN) has a StockPik Value Score of 45 out of 100 — a mid-range score, indicating moderate value characteristics. The Value Score is a composite ranking built from P/E ratio, P/B ratio, Graham Number, ROE, gross margin, debt-to-equity, current ratio, and Piotroski F-Score, calculated from SEC EDGAR annual filing data.

What is NNNN's Piotroski F-Score?

Anbio Biotechnology - Class A Ordinary Shares (NNNN) has a Piotroski F-Score of 4 out of 9 — a moderate score. The F-Score assesses nine binary financial criteria across profitability, leverage, and operating efficiency. A score of 7–9 indicates a financially improving company; a score of 0–3 is a warning sign.

Is NNNN trading below its Graham Number?

NNNN is currently trading above its Graham Number. The stock price of $25.35 exceeds the Graham Number of $1.51, meaning it does not meet Graham's criterion for a margin of safety at the current price. The Graham Number is calculated as √(22.5 × EPS × Book Value Per Share) and represents Benjamin Graham's ceiling price for a defensive investor.

What is NNNN's Graham Number?

NNNN's Graham Number is $1.51, calculated using the Benjamin Graham formula √(22.5 × EPS × Book Value per Share). The Graham Number is an estimate of intrinsic value — the maximum price a defensive investor should pay. At the current price of $25.35, NNNN is trading 1,580% above its Graham Number.

What is NNNN's Piotroski F-Score?

NNNN's Piotroski F-Score is 4 out of 9, indicating moderate financial health. The Piotroski F-Score evaluates nine criteria across profitability, leverage, and operating efficiency. Scores of 7 or above are considered strong; 3 or below indicate financial weakness.

Is NNNN (Anbio Biotechnology - Class A Ordinary Shares) undervalued?

NNNN scores 45/100 on StockPik's Value Score. The stock trades 1,580% above its Graham Number of $1.51.

What is NNNN's P/E ratio?

NNNN's trailing P/E ratio is 172.9x — an elevated earnings multiple, potentially pricing in high growth expectations. The Healthcare sector average P/E is 25.2x. Compare against other Healthcare stocks in the StockPik screener.

What sector is Anbio Biotechnology - Class A Ordinary Shares (NNNN) in?

Anbio Biotechnology - Class A Ordinary Shares (NNNN) is in the Healthcare sector, specifically in the In Vitro & In Vivo Diagnostic Substances industry. Compare it against other Healthcare stocks by Value Score, P/E ratio, and Piotroski F-Score on StockPik.

Back to Screener

Anbio Biotechnology - Class A Ordinary Shares (NNNN)

NASDAQ Small Cap

Healthcare › In Vitro & In Vivo Diagnostic Substances

$25.35

Market Cap: $1.1B

Data as of Dec 31, 2025

Price History

Feb 9, 2026 — May 12, 2026

Investment Snapshot

Trading 1,580% above Graham Number — above intrinsic value estimate
Piotroski F-Score 4/9 — moderate financial health
Strong ROE of 21.2% with 74.1% net margin
Revenue growing at 6% annually

Anbio Biotechnology - Class A Ordinary Shares (NNNN) is a Healthcare company operating in In Vitro & In Vivo Diagnostic Substances, listed on the NASDAQ , with a market capitalisation of $1.1 billion . Key value metrics: P/E ratio 172.9, P/B ratio 36.71, Piotroski F-Score 4 out of 9 (moderate financial health) .

Value Score

out of 100

Try PRO Free — See Full Breakdown

Key Metrics

P/E Ratio

172.89

P/B Ratio

36.71

EPS

$0.15

Div. Yield

—

PEG Ratio

—

P/S Ratio

—

EV/EBITDA

—

ROE

—

ROA

—

Gross Margin

—

Op. Margin

—

Net Margin

—

Debt/Equity

—

Current Ratio

—

Unlock 19 More Metrics — 7 Days Free

Current vs 5-Year Average

Based on 3 years of SEC filings

Net Margin

—

↑ +2.1pp avg —

Gross Margin

—

↑ +2.1pp avg —

Operating Margin

—

↑ +2.1pp avg —

Return on Equity

—

↑ +2.1pp avg —

Debt / Equity

—

↑ +2.1pp avg —

See How Margins & ROE Have Trended — Try PRO

Revenue & Net Income

Profit Margins

Track Gross, Operating & Net Margins — Try PRO

EPS & Free Cash Flow Per Share

See EPS & Free Cash Flow Trends — Try PRO

Financial Statements

Metric	FY22	FY23	FY24
Revenue	$X.XB	$X.XB	$X.XB
Gross Profit	$X.XB	$X.XB	$X.XB
Operating Income	$X.XB	$X.XB	$X.XB
Net Income	$X.XB	$X.XB	$X.XB
EBITDA	$X.XB	$X.XB	$X.XB
Total Assets	$X.XB	$X.XB	$X.XB
Total Liabilities	$X.XB	$X.XB	$X.XB

Unlock 5 Years of Financials — Start Free Trial

Data sourced from SEC EDGAR and Polygon.io. Methodology. View more Healthcare stocks →

Anbio Biotechnology - Class A Ordinary Shares — Fundamental Analysis Summary

Anbio Biotechnology - Class A Ordinary Shares (NNNN) is currently trading 1,580% above its Graham Number of $1.51, suggesting the market price exceeds Benjamin Graham's intrinsic value estimate. The stock carries an elevated trailing P/E ratio of 172.9x.

On financial health, NNNN shows a moderate Piotroski F-Score of 4/9, and strong return on equity of 21.2% (sector average: -20.6%), and minimal leverage with a debt-to-equity ratio of 0.10.

StockPik's composite Value Score for NNNN is 45/100 — reflecting current market or financial concerns. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.

NNNN reports a high gross margin of 87.2% (sector average: 40.1%) and a strong operating margin of 66.7%.

NNNN shows revenue growing at 6% year-over-year, with earnings growing at 170%.

Top Value Stocks in Healthcare

Symbol	Name	Price	P/E	Score
EMBC	Embecta Corp. - Common Stock	$3.90	2.1	100
HCM	HUTCHMED (China) Limited - American Depositary Shares	$13.31	5.1	100
GMAB	Genmab A/S - American Depositary Shares	$27.06	1.8	100
CGEN	Compugen Ltd. - Ordinary Shares	$2.71	7.3	100
INVA	Innoviva, Inc. - Common Stock	$22.89	5.8	100

Browse all Healthcare value stocks →

How is the Value Score calculated?

Read our full methodology →

How is the Graham Number calculated?

Benjamin Graham's intrinsic value formula, worked examples, and how to use it →

NNN — NNN REIT, Inc. Common Stock

NANO-X IMAGING LTD - Ordinary Shares — NNOX